Literature DB >> 19762373

Using a longitudinal model to estimate the effect of methicillin-resistant Staphylococcus aureus infection on length of stay in an intensive care unit.

Adrian G Barnett1, Rahul Batra, Nicholas Graves, Jonathan Edgeworth, Julie Robotham, Ben Cooper.   

Abstract

Health-care-associated methicillin-resistant Staphylococcus aureus (MRSA) infection may cause increased hospital stay, or sometimes death. Quantifying this effect is complicated because the exposure is time dependent: infection may prolong hospital stay, while longer stays increase infection risk. In this paper, the authors overcome these problems by using a multinomial longitudinal model to estimate the daily probability of death and discharge. They then extend the basic model to estimate how the effect of MRSA infection varies over time and to quantify number of excess days in the intensive care unit due to infection. They found that infection decreased the relative risk of discharge (relative risk ratio = 0.68, 95% credible interval: 0.54, 0.82). Infection on the first day of admission resulted in a mean extra stay of 0.3 days (95% credible interval: 0.1, 0.5) for a patient with an Acute Physiology and Chronic Health Evaluation II score of 10 and 1.2 days (95% credible interval: 0.5, 2.0) for a patient with a score of 30. The decrease in the relative risk of discharge remained fairly constant with day of MRSA infection but was slightly stronger closer to the start of infection. Results confirm the importance of MRSA infection in increasing stay in an intensive care unit but suggest that previous work may have systematically overestimated the effect size.

Entities:  

Mesh:

Year:  2009        PMID: 19762373     DOI: 10.1093/aje/kwp249

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  9 in total

1.  On the role of length of stay in healthcare-associated bloodstream infection.

Authors:  Christie Y Jeon; Matthew Neidell; Haomiao Jia; Matt Sinisi; Elaine Larson
Journal:  Infect Control Hosp Epidemiol       Date:  2012-10-19       Impact factor: 3.254

2.  Choosing between methods to prevent methicillin-resistant Staphylococcus aureus in ICUs*.

Authors:  Daniel J Morgan
Journal:  Crit Care Med       Date:  2015-02       Impact factor: 7.598

3.  Quantifying cost-effectiveness of controlling nosocomial spread of antibiotic-resistant bacteria: the case of MRSA.

Authors:  Marjan W M Wassenberg; G Ardine de Wit; Ben A van Hout; Marc J M Bonten
Journal:  PLoS One       Date:  2010-07-16       Impact factor: 3.240

4.  Prolongation of length of stay and Clostridium difficile infection: a review of the methods used to examine length of stay due to healthcare associated infections.

Authors:  Brett G Mitchell; Anne Gardner
Journal:  Antimicrob Resist Infect Control       Date:  2012-04-20       Impact factor: 4.887

5.  Screening, isolation, and decolonisation strategies in the control of meticillin resistant Staphylococcus aureus in intensive care units: cost effectiveness evaluation.

Authors:  Julie V Robotham; Nicholas Graves; Barry D Cookson; Adrian G Barnett; Jennie A Wilson; Jonathan D Edgeworth; Rahul Batra; Brian H Cuthbertson; Ben S Cooper
Journal:  BMJ       Date:  2011-10-05

6.  Quantifying type-specific reproduction numbers for nosocomial pathogens: evidence for heightened transmission of an Asian sequence type 239 MRSA clone.

Authors:  Ben S Cooper; Theodore Kypraios; Rahul Batra; Duncan Wyncoll; Olga Tosas; Jonathan D Edgeworth
Journal:  PLoS Comput Biol       Date:  2012-04-12       Impact factor: 4.475

7.  Acid sphingomyelinase inhibition protects mice from lung edema and lethal Staphylococcus aureus sepsis.

Authors:  Huiming Peng; Cao Li; Stephanie Kadow; Brian D Henry; Jörg Steinmann; Katrin Anne Becker; Andrea Riehle; Natalie Beckmann; Barbara Wilker; Pin-Lan Li; Timothy Pritts; Michael J Edwards; Yang Zhang; Erich Gulbins; Heike Grassmé
Journal:  J Mol Med (Berl)       Date:  2015-01-25       Impact factor: 4.599

8.  The economic burden of patient safety targets in acute care: a systematic review.

Authors:  Nicole Mittmann; Marika Koo; Nick Daneman; Andrew McDonald; Michael Baker; Anne Matlow; Murray Krahn; Kaveh G Shojania; Edward Etchells
Journal:  Drug Healthc Patient Saf       Date:  2012-10-05

9.  Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis.

Authors:  A Richter; J Listing; M Schneider; T Klopsch; A Kapelle; J Kaufmann; A Zink; A Strangfeld
Journal:  Ann Rheum Dis       Date:  2015-11-13       Impact factor: 19.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.